Datopotamab Deruxtecan, often abbreviated as DATO, represents the important advancement within targeted cancer care. This innovative antibody-drug conjugate joins an monoclonal antibody specifically directed at HER2 https://dirstop.com/story28112653/datopotamab-deruxtecan-an-hopeful-adc-compound